FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response	: 0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Grossman Jessica D.		F (Date of Event Requiring Staten Month/Day/Year 04/09/2018	nent T	3. Issuer Name and Ticker or Trading Symbol Dare Bioscience, Inc. [DARE]						
(Last) (First) (Middle) C/O DARE BIOSCIENCE, INC.					Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				5. If Amendment, Date of Original Filed (Month/Day/Year)		
11119 NORTH TORREY PINES ROAD, SUITE 200					Officer (give below)	Officer (give title below)	Other (spe below)	, 10.	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person		
(Street) LA JOLLA	CA	92037								y More than One	
(City)	(State)	(Zip)									
		_			<u> </u>		· · Ourmad				
		I	able I - Non	ı-Derivativ	ve Securities E	seneticiali	y Owned				
1. Title of Secur	ity (Instr. 4)	1	able I - Non	2.	Amount of Securit eneficially Owned (ies	3. Ownersh Form: Direct or Indirect (Instr. 5)	ct (D) (Ins	lature of Indirect tr. 5)	Beneficial Ownership	
1. Title of Secur	ity (Instr. 4)		Table II - D	2. Be	Amount of Securit	ies Instr. 4) neficially (3. Ownersh Form: Direct or Indirect (Instr. 5)	et (D) (Ins		Beneficial Ownership	
Title of Secur Title of Deriva	, ,	(e. <u>ç</u>	Table II - D	2. Be Derivative Is, warran cisable and	Amount of Securit eneficially Owned (Securities Bei	neficially (3. Ownersh Form: Direct or Indirect (Instr. 5) Owned securitie	et (D) (Ins	5. Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)	

Explanation of Responses:

Remarks:

No securities are beneficially owned.

No securities are beneficially owned.

/s/ Jenna M. Stewart, Attorneyin-fact 04/11/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Sabrina Martucci Johnson, the Chief Executive Officer of Dare Bioscience, Inc. (the "Company"), Lisa Walters-Hoffert, the Chief Financial Officer of the Company, Edwin Astudillo of Breakwater Law Group, and Jeremy D. Glaser, Sebastian E. Lucier, Jenna M. Stewart, Patrick Elahmadie, Christian Hollweg, Joan Raulston and Brenda Meyette of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such forms and authentication documents;
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 4th day of April, 2018.

/s/ Jessica D. Grossman Signature

Name: Jessica D. Grossman